TRVN - トレベナ （Trevena Inc.） トレベナTRVNのチャート
TRVNの企業情報
| symbol | TRVN |
|---|---|
| 会社名 | Trevena Inc （トレベナ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 トレベナ(Trevena Inc.)は多様な治療法の開発に従事するバイオ医薬品会社である。同社は静脈内（IV）投与が好ましい中等度から重度の急性疼痛の管理のためのu-受容体Gタンパク質経路選択モジュレーター（u-GPS）であるOLINVOを開発中である。同社は病院と外来手術センターなどの急性ケア施設で使用するために米国で商業化することを主とする。また、片頭痛の治療のための非麻薬性機構を有する化合物として、o-受容体を標的とするGタンパク質偏向リガンドであるTRV250を開発している。TRV250はまた、他の中枢神経系（CNS）適応症に使用される。同社は英国でTRV250の第I相試験開始に焦点を当てる。そのABLE製品プラットフォームは、多様な医薬品特性を持つユニークなGタンパク質共役型受容体（GPCR）標的化リガンドを同定するために使用される生物学的情報、インビトロアッセイ、ノウハウおよび専門知識のコレクションである。 トレベナは米国のバイオ医薬品会社で、Gタンパク質共役受容体(GPCR)をタ―ゲットにした治療薬の開発に焦点を置く。中度から重度の疼痛に対する点滴剤TRV130と経口剤TRV734のほか、急性心疾患の点滴剤TRV027治験を行う。また、難治性片頭痛の経口剤TRV250の開発を行う。 Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders. |
| 本社所在地 | 955 Chesterbrook Boulevard Suite 200 Chesterbrook PA 19087 USA |
| 代表者氏名 | Leon O. Moulder レオン・O・モルダー |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 610-354-8840 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.trevenainc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/trvn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -45.30600 |
| 終値（lastsale） | 2.98 |
| 時価総額（marketcap） | 226725194.4 |
| 時価総額 | 時価総額（百万ドル） 72.04992 |
| 売上高 | 売上高（百万ドル） 2.50000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 31.94392 |
| 当期純利益 | 当期純利益（百万ドル） -49.04400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Trevena Inc revenues increased from $0K to $2.5M. Net loss decreased 55% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 70% to $9M (expense) Miscellaneous income increase from $628K to $1.4M (income). |
TRVNのテクニカル分析
TRVNのニュース
Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript 2023/03/31 19:07:10 Seeking Alpha
Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsBarry Shin - Chief Financial OfficerCarrie Bourdow - President and Chief…
Trevena Post Op Pain Management Drug Cuts Hospital Stay Length Vs. Patients On Opioids 2023/03/30 17:52:00 Benzinga
Trevena Inc (NASDAQ: TRVN ) announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS. The VOLITION study (n=203 patients) assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. Initial GI and cognition data are available, with respiratory outcome data expected in mid-2023. OLINVYK-treated patients had a 52.2% GI … Full story available on Benzinga.com
Trevena stock rises after opioid pain drug Olinvyk shows promise in trial 2023/03/30 11:44:17 Seeking Alpha
Trevena (TRVN) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine). Read more here.
Earnings Scheduled For March 30, 2023 2023/03/30 11:24:25 Benzinga
Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.
Trevena: Q4 Earnings Snapshot 2023/03/30 11:21:34 WTOP
CHESTERBROOK, Pa. (AP) — CHESTERBROOK, Pa. (AP) — Trevena Inc. (TRVN) on Thursday reported a loss of $7 million in…
Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript 2023/03/31 19:07:10 Seeking Alpha
Trevena, Inc. (NASDAQ:NASDAQ:TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ETCompany ParticipantsBarry Shin - Chief Financial OfficerCarrie Bourdow - President and Chief…
Trevena Post Op Pain Management Drug Cuts Hospital Stay Length Vs. Patients On Opioids 2023/03/30 17:52:00 Benzinga
Trevena Inc (NASDAQ: TRVN ) announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS. The VOLITION study (n=203 patients) assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. Initial GI and cognition data are available, with respiratory outcome data expected in mid-2023. OLINVYK-treated patients had a 52.2% GI … Full story available on Benzinga.com
Trevena stock rises after opioid pain drug Olinvyk shows promise in trial 2023/03/30 11:44:17 Seeking Alpha
Trevena (TRVN) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine). Read more here.
Earnings Scheduled For March 30, 2023 2023/03/30 11:24:25 Benzinga
Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.
Trevena: Q4 Earnings Snapshot 2023/03/30 11:21:34 WTOP
CHESTERBROOK, Pa. (AP) — CHESTERBROOK, Pa. (AP) — Trevena Inc. (TRVN) on Thursday reported a loss of $7 million in…
Trevena Q2 2022 Earnings Preview (NASDAQ:TRVN) 2022/08/10 17:41:42 Seeking Alpha
Trevena (TRVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open.The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue…
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022 2022/08/08 11:00:00 GlobeNewswire
Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET
Trevena Inc. (TRVN) can beat the pack with these strategies 2022/08/02 14:16:00 US Post News
Trevena Inc. (NASDAQ:TRVN) marked $0.22 per share on Monday, down from a previous closing price of $0.25. While Trevena Inc. has underperformed by -10.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TRVN fell by -83.37%, with highs and lows ranging from $1.54 to $0.18, whereas […]
Should This Make Trevena Inc. (NASDAQ: TRVN) Investors Worry? 2022/08/01 13:30:00 Stocks Register
The trading price of Trevena Inc. (NASDAQ:TRVN) closed lower on Friday, July 29, closing at $0.25, -5.67% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.2366 and $0.254. In examining the 52-week price action we see that the stock hit a 52-week high … Should This Make Trevena Inc. (NASDAQ: TRVN) Investors Worry? Read More »
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock 2022/07/29 21:27:00 GlobeNewswire
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock (“Series A Preferred”) and 200 shares of Series B convertible preferred stock (“Series B Preferred”) and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company’s common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance.